Executive Vice President
Kirsten was named executive vice president and president, Pfizer Global Supply (PGS) in December 2016 and is responsible for Pfizer’s internal and external supply network. Kirsten's pharmaceutical industry career spans 30 years, the last 17 with Pfizer, after joining the company from SmithKline Beecham in 1999 as vice president, global supply chain management, Pharmaceuticals. At SmithKline Beecham (Germany, Australia and the U.S.), Kirsten held several operational and functional roles, including site leader of consumer and pharmaceutical plants; vice president, global strategic planning; and vice president, contractor management, Europe. Kirsten was named vice president, supply chain management for all Pfizer global businesses in 2000. She then led the Patented Products Operating Unit (Manufacturing Sites in Europe and Singapore) 2008-2009, and the Primary Care and Oncology, Operating Unit (Manufacturing Sites in Europe, Singapore, Canada) 2009-2012. Kirsten was named vice president, Product Portfolio Management for Primary Care, Established Products and Oncology in 2012. Kirsten was appointed as product portfolio management lead and PGS lead for Vaccines, Oncology, and Consumer in 2014 and subsequently vice president, Innovative Health Product Portfolio Management and Consumer Operations. Kirsten has been a member of the PGS Leadership Team since 2000, and was the PGS lead on several of Pfizer’s Business Leadership Teams (Pfizer Consumer, Primary Care, Specialty Care, Established Products and Pfizer Innovative Health) driving collaboration between global supply and commercial teams. Kirsten was elected to the Pfizer Foundation Board in 2008. She chaired Pfizer’s Environmental Sustainability Council from 2009 through 2016 and was named Executive Leadership Team (ELT) sponsor for Pfizer’s Environmental Sustainability program in 2017. Kirsten is a pharmacist from Kiel University in Germany and holds a Ph.D. in Pharmaceutical Biology from Freiburg University in Germany.
Clinical data management, Clinical trails, Pharmacovigilance